Basal cell carcinoma - metastatic or locally advanced

The PBS subsidises sonidegib and vismodegib for patients with metastatic or locally advanced basal cell carcinoma (BCC).

Patient eligibility

Treatment with sonidegib and vismodegib can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, Section 85 for a patient with metastatic or locally advanced basal cell carcinoma.

Patients must be eligible for the PBS and meet the relevant restriction criteria..

The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing sonidegib and vismodegib.

Applications

Initial treatment

Make all initial applications for authority approval to prescribe sonidegib or vismodegib for the treatment of metastatic or locally advanced BCC in writing and:

All applications must include the completed:

Continuing treatment

Make all applications for continuing authority approval to prescribe sonidegib or vismodegib for the treatment of metastatic or locally advanced BCC in writing and:

All applications must include the completed:

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 April 2018